17-05-2014, 12:22 PM
A belated post...following Frencken's Q1 earnings :
http://infopub.sgx.com/Apps?A=COW_CorpAn...esults.pdf
Revenues.
Q1 2013 : 107,240
Q2 2013 : 108,469
Q3 2013 : 119,601
Q4 2013 : 109,427
Q1 2014 : 110,904
Gross Profit (% margin)
Q1 2013 : 15,142 (14.1%)
Q2 2013 : 16,913 (15.6%)
Q3 2013 : 19,493 (16.3%)
Q4 2013 : 15,388 (14.1%)
Q1 2014 : 17,315 (15.6%)
Net Profit (% margin)
Q1 2013 : 3,240 (3.0%)
Q2 2013 : 4,150 (3.8%)
Q3 2013 : 6,933 (5.8%)
Q4 2013 : 3,809 (3.5%)
Q1 2014 : 3,848 (3.5%)
Note that Management highlighted, at the time of the Q3 2013 earnings, that these were extraordinarily high (due to higher orders and FX) and should not be extrapolated to future earnings.
Trailing 12 months revenues of $448MM are roughly flat with 2013 full year revenues of$444MM but gross profit ($69.1MM vs $66.9MM) and net earnings ($18.7MM vs 18.1MM) are slightly higher. Trailing EPS is at 4.61 cents vs 4.47 cents giving a trailing PE of 7.6x which still seems reasonable. NAV of 52.15 cents vs share price of 35 cents so a 33% discount and a dividend yield of 4% based on the 2013 dividend of 1.40 cents.
Revenues continue to be diversified from various industrial sectors (see below) which is why I continue to like it as a diversified play on global manufacturing growth
Segment revenues (Q1 2014 vs Q1 2013)
Semi-conductor : 16.6MM vs 9.8MM
Medical : 16.8MM vs 17.2MM
Analytical : 22MM vs. 22.4MM
Industrial Automation : 6.7MM vs 8.9MM
Office Automation : 5.8MM vs 7.4MM
Automotive : 28.1MM vs 23.2MM
Consumer & Industrial Electornics : 5.2MM vs. 6.2MM
Tooling : 3.4MM vs 2.7MM
Others : 8.3MM vs. 9.4MM
Much of the companies growth in revenues and improvements in margins have followed the acquisition of Juken (now folded into the various product lines) in late 2012. Margins have also benefited from a turn-around in their Malaysian manufacturing and lastly, a large part of their revenues go to Europe so a strong EUR helps margins. The last point is worth monitoring given the ECB's concerns over a strong EUR and likely easing of monitary policy in June. So some potential headwinds and we are unlikely to see the kind of strong growth in earnings witnessed over the past few years. However, still seems like a cheap proxy for global growth with both earnings growth potential and a PE re-rerating potential.
Lastly, the company has just announced that CEO is taking a medical leave of absence. Not a good thing but hopefully the management bench is deep enough to handle the company until he returns.
(vested)
http://infopub.sgx.com/Apps?A=COW_CorpAn...esults.pdf
Revenues.
Q1 2013 : 107,240
Q2 2013 : 108,469
Q3 2013 : 119,601
Q4 2013 : 109,427
Q1 2014 : 110,904
Gross Profit (% margin)
Q1 2013 : 15,142 (14.1%)
Q2 2013 : 16,913 (15.6%)
Q3 2013 : 19,493 (16.3%)
Q4 2013 : 15,388 (14.1%)
Q1 2014 : 17,315 (15.6%)
Net Profit (% margin)
Q1 2013 : 3,240 (3.0%)
Q2 2013 : 4,150 (3.8%)
Q3 2013 : 6,933 (5.8%)
Q4 2013 : 3,809 (3.5%)
Q1 2014 : 3,848 (3.5%)
Note that Management highlighted, at the time of the Q3 2013 earnings, that these were extraordinarily high (due to higher orders and FX) and should not be extrapolated to future earnings.
Trailing 12 months revenues of $448MM are roughly flat with 2013 full year revenues of$444MM but gross profit ($69.1MM vs $66.9MM) and net earnings ($18.7MM vs 18.1MM) are slightly higher. Trailing EPS is at 4.61 cents vs 4.47 cents giving a trailing PE of 7.6x which still seems reasonable. NAV of 52.15 cents vs share price of 35 cents so a 33% discount and a dividend yield of 4% based on the 2013 dividend of 1.40 cents.
Revenues continue to be diversified from various industrial sectors (see below) which is why I continue to like it as a diversified play on global manufacturing growth
Segment revenues (Q1 2014 vs Q1 2013)
Semi-conductor : 16.6MM vs 9.8MM
Medical : 16.8MM vs 17.2MM
Analytical : 22MM vs. 22.4MM
Industrial Automation : 6.7MM vs 8.9MM
Office Automation : 5.8MM vs 7.4MM
Automotive : 28.1MM vs 23.2MM
Consumer & Industrial Electornics : 5.2MM vs. 6.2MM
Tooling : 3.4MM vs 2.7MM
Others : 8.3MM vs. 9.4MM
Much of the companies growth in revenues and improvements in margins have followed the acquisition of Juken (now folded into the various product lines) in late 2012. Margins have also benefited from a turn-around in their Malaysian manufacturing and lastly, a large part of their revenues go to Europe so a strong EUR helps margins. The last point is worth monitoring given the ECB's concerns over a strong EUR and likely easing of monitary policy in June. So some potential headwinds and we are unlikely to see the kind of strong growth in earnings witnessed over the past few years. However, still seems like a cheap proxy for global growth with both earnings growth potential and a PE re-rerating potential.
Lastly, the company has just announced that CEO is taking a medical leave of absence. Not a good thing but hopefully the management bench is deep enough to handle the company until he returns.
(vested)